PARIS, France—Left atrial appendage (LAA) occlusion with the Amplatzer Amulet (Abbott) reduces the risk of ischemic stroke in real-world use through 2 years, for the most part without the need for ...
First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...
First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise ...
Abbott Laboratories received FDA approval for its Amplatzer Amulet left atrial appendage occluder to treat people with atrial fibrillation who are at risk of ischemic stroke about a month earlier than ...
(UPDATED) In patients undergoing left atrial appendage (LAA) occlusion, the Amplatzer Amulet device (Abbott) provides better closure as well as noninferior safety and effectiveness compared with the ...
Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...
New Guidelines Issued for Management of Atrial Fibrillation The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology. Using dual-seal ...
The Amplatzer Piccolo Occluder received FDA approval and CE Mark in 2019. "We designed the Amplatzer Piccolo Delivery System based on feedback from leading physicians across the world to make PDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results